ILEX Oncology Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 216

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1B

ILEX Oncology General Information

Description

Developer of cancer therapeutics. The company focuses on accelerated development of drugs for the treatment and prevention of cancer. Its lead pipeline candidate is clofarabine, a next-generation purine nucleoside analogue that inhibits both DNA and RNA synthesis. The company is investigating clofarabine for use in pediatric and adult acute leukemias, as well as advanced solid tumors.

Contact Information

Website
www.ilexonc.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4545 Horizon Hill Boulevard
  • San Antonio, TX 78229
  • United States
+1 (210)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Sanofi Genzyme
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4545 Horizon Hill Boulevard
  • San Antonio, TX 78229
  • United States
+1 (210)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ILEX Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 21-Dec-2004 $1B Completed Generating Revenue
6. IPO 21-Feb-1997 Completed Startup
5. Later Stage VC (Series E) Completed Startup
4. Later Stage VC (Series D) 14-Feb-1997 Completed Startup
3. Later Stage VC (Series C) 08-Nov-1996 Completed Startup
2. Early Stage VC (Series B) 19-Jul-1996 $6.2M $11.7M Completed Startup
1. Early Stage VC (Series A) $5.53M $5.53M Completed Startup
To view ILEX Oncology’s complete valuation and funding history, request access »

ILEX Oncology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series E
Series D
Series C
Series B 5,432,500 $0.010000 $0.16 $2 $2 1x $2 15.77%
Series A 5,239,900 $0.010000 $0.15 $1.85 $1.85 1x $1.85 15.21%
To view ILEX Oncology’s complete cap table history, request access »

ILEX Oncology Patents

  • 36

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

ILEX Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20060057107-A1 Combination treatment for multiple sclerosis Inactive 21-Dec-2001
AU-2002360696-A1 Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis Inactive 21-Dec-2001
AU-2002360696-A8 Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis Inactive 21-Dec-2001
EP-1455826-A2 Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment of multiple sclerosis Inactive 21-Dec-2001
JP-2005504036-A Method for preparing purine nucleosides Active 02-Aug-2001 C07H19/16
To view ILEX Oncology’s complete patent history, request access »

ILEX Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ILEX Oncology Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Boston Capital Ventures Venture Capital Minority
Synthesis Capital (Boston) Venture Capital Minority
To view ILEX Oncology’s complete investors history, request access »

Ready to get started?

Request a free trial

ILEX Oncology FAQs

  • When was ILEX Oncology founded?

    ILEX Oncology was founded in 1992.

  • Where is ILEX Oncology headquartered?

    ILEX Oncology is headquartered in San Antonio, TX.

  • What is the size of ILEX Oncology?

    ILEX Oncology has 216 total employees.

  • What industry is ILEX Oncology in?

    ILEX Oncology’s primary industry is Biotechnology.

  • Is ILEX Oncology a private or public company?

    ILEX Oncology is a Private company.

  • What is the current valuation of ILEX Oncology?

    The current valuation of ILEX Oncology is .

  • What is ILEX Oncology’s current revenue?

    The current revenue for ILEX Oncology is .

  • How much funding has ILEX Oncology raised over time?

    ILEX Oncology has raised $53M.

  • Who are ILEX Oncology’s investors?

    Alta Partners, Boston Capital Ventures, and Synthesis Capital (Boston) have invested in ILEX Oncology.

  • When was ILEX Oncology acquired?

    ILEX Oncology was acquired on 21-Dec-2004.

  • Who acquired ILEX Oncology?

    ILEX Oncology was acquired by Sanofi Genzyme.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »